Correlation Between Inhibrx and Nuvectis Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Inhibrx and Nuvectis Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibrx and Nuvectis Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inhibrx and Nuvectis Pharma, you can compare the effects of market volatilities on Inhibrx and Nuvectis Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibrx with a short position of Nuvectis Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibrx and Nuvectis Pharma.

Diversification Opportunities for Inhibrx and Nuvectis Pharma

0.42
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Inhibrx and Nuvectis is 0.42. Overlapping area represents the amount of risk that can be diversified away by holding Inhibrx and Nuvectis Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Nuvectis Pharma and Inhibrx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibrx are associated (or correlated) with Nuvectis Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Nuvectis Pharma has no effect on the direction of Inhibrx i.e., Inhibrx and Nuvectis Pharma go up and down completely randomly.

Pair Corralation between Inhibrx and Nuvectis Pharma

Given the investment horizon of 90 days Inhibrx is expected to generate 0.35 times more return on investment than Nuvectis Pharma. However, Inhibrx is 2.88 times less risky than Nuvectis Pharma. It trades about -0.01 of its potential returns per unit of risk. Nuvectis Pharma is currently generating about 0.0 per unit of risk. If you would invest  1,595  in Inhibrx on September 3, 2024 and sell it today you would lose (69.00) from holding Inhibrx or give up 4.33% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Inhibrx  vs.  Nuvectis Pharma

 Performance 
       Timeline  
Inhibrx 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Inhibrx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental drivers, Inhibrx is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.
Nuvectis Pharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Nuvectis Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental indicators, Nuvectis Pharma is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.

Inhibrx and Nuvectis Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Inhibrx and Nuvectis Pharma

The main advantage of trading using opposite Inhibrx and Nuvectis Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibrx position performs unexpectedly, Nuvectis Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nuvectis Pharma will offset losses from the drop in Nuvectis Pharma's long position.
The idea behind Inhibrx and Nuvectis Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Other Complementary Tools

Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences